Target trial emulation (TTE) has gained popularity in evaluating treatments and health interventions. Its application to infectious disease outcomes requires careful consideration, as infectious disease transmission violates the assumption of no interference. Thus, we conducted a scoping review to understand how TTE approaches have been applied to vaccine evaluation. We searched literature published in PubMed, Embase, and Web of Science until May 2024, using keywords related to TTE, infectious diseases, and vaccines. Full-text articles meeting inclusion criteria were further assessed for eligibility. Our keyword-based search and citation search identified a total of 241 studies. Of these, 35 original research studies used TTE approaches to evaluate vaccines, predominantly published from 2022 to 2024. The majority (n=32, 91%) evaluated the effect of COVID-19 vaccines, with one study each evaluating influenza, mpox, and rotavirus vaccines. Most studies did not define which of the four effects of vaccination they evaluated (direct, indirect, total, or overall effect), and none incorporated interference in vaccine evaluation. Our review highlights the increasing popularity of TTE in vaccine evaluation following the COVID-19 pandemic. Further discussions are needed to establish TTE approaches to estimating four effects of vaccination, using large, routinely collected data.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/aje/kwaf053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Better Together: Implementation of a Public Health Learning Community During the COVID-19 Pandemic.
Am J Public Health
April 2025
Kristen M. Brown, Brigette Courtot, Zara Porter, and Sofia Hinojosa are with the Health Policy Center, Urban Institute, Washington, DC.
The Centers for Disease Control and Prevention's Partnering for Vaccine Equity program was developed during the COVID-19 public health emergency to fund more than 500 community-based organizations working to improve vaccine equity. Organizations were supported by a virtual learning community where members received tailored learning content, peer-to-peer learning opportunities, and resources that facilitated deployment of vaccine-related programming during a dynamic pandemic. Process evaluation metrics indicate successful implementation of the learning community.
View Article and Find Full Text PDFRapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies.
J Immunol
February 2025
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Several vaccines and immunization strategies, including inactivated vaccines, have proven effective in eliciting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), providing an opportunity to characterize the antibody response. In this study, we investigated the monoclonal antibody responses elicited by wild-type SARS-CoV-2 inactivated vaccination compared to those elicited by natural infection and mRNA vaccination. The analysis showed that antibodies encoded by biased germline genes were shared between SARS-CoV-2 vaccinated and naturally infected individuals.
View Article and Find Full Text PDFComparison of human macrophages derived from peripheral blood and bone marrow.
J Immunol
March 2025
Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Macrophage differentiation, phenotype, and function have been assessed extensively in vitro by predominantly deriving human macrophages from peripheral blood. It is accepted that there are differences between macrophages isolated from different human tissues; however, the importance of anatomical source for in vitro differentiation and characterization is less clear. Here, phenotype and function were evaluated between human macrophages derived from bone marrow or peripheral blood.
View Article and Find Full Text PDFDifferential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist.
J Immunol
February 2025
Gritstone Bio, Inc, Emeryville, CA, United States.
While therapeutic vaccines are a promising strategy for inducing human immunodeficiency virus (HIV) control, HIV vaccines tested to date have offered limited benefit to people living with HIV. The barriers to success may include the use of vaccine platforms and/or immunogens that drive weak or suboptimal immune responses, immune escape and/or immune dysfunction associated with chronic infection despite effective antiretroviral therapy. Combining vaccines with immune modulators in a safe manner may address some of the challenges and thus increase the efficacy of therapeutic HIV vaccines.
View Article and Find Full Text PDFNeoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model.
Cancer Immunol Immunother
March 2025
Medical Genetics Institute, Ho Chi Minh City, Vietnam.
Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly in the context of tumor burden (TB), remains insufficiently studied. In this research, we evaluated the safety and therapeutic efficacy of synthetic long peptide and mRNA-based vaccines, both designed to target identical neoantigens across different Lewis Lung Carcinoma (LLC) tumor burdens. We employed the LLC syngeneic mouse model, a widely used preclinical model for aggressive and immunosuppressive tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!